New York Life Investment Management LLC Buys New Shares in Spyre Therapeutics, Inc. $SYRE

New York Life Investment Management LLC purchased a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) in the third quarter, HoldingsChannel reports. The fund purchased 11,660 shares of the company’s stock, valued at approximately $1,038,000.

Several other hedge funds also recently made changes to their positions in SYRE. GAMMA Investing LLC grew its stake in shares of Spyre Therapeutics by 26.8% during the 2nd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $59,000 after acquiring an additional 140 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Spyre Therapeutics by 4.4% in the third quarter. Allspring Global Investments Holdings LLC now owns 6,355 shares of the company’s stock worth $572,000 after purchasing an additional 265 shares in the last quarter. AlphaCentric Advisors LLC lifted its position in shares of Spyre Therapeutics by 4.3% in the third quarter. AlphaCentric Advisors LLC now owns 6,956 shares of the company’s stock worth $619,000 after purchasing an additional 286 shares in the last quarter. Integrated Wealth Concepts LLC bought a new stake in shares of Spyre Therapeutics in the second quarter worth $31,000. Finally, Nisa Investment Advisors LLC boosted its holdings in Spyre Therapeutics by 24.3% during the third quarter. Nisa Investment Advisors LLC now owns 2,918 shares of the company’s stock worth $260,000 after purchasing an additional 571 shares during the last quarter. 80.39% of the stock is owned by institutional investors.

Spyre Therapeutics Price Performance

NASDAQ:SYRE opened at $104.00 on Monday. The firm has a market capitalization of $9.88 billion, a price-to-earnings ratio of -37.96 and a beta of 3.24. Spyre Therapeutics, Inc. has a twelve month low of $22.13 and a twelve month high of $110.64. The stock’s 50 day moving average price is $91.48 and its two-hundred day moving average price is $76.31.

Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). As a group, analysts anticipate that Spyre Therapeutics, Inc. will post -2.78 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on SYRE shares. Wolfe Research downgraded shares of Spyre Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Tuesday, July 28th. Wall Street Zen cut shares of Spyre Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 31st. Wells Fargo & Company boosted their price target on shares of Spyre Therapeutics from $90.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. UBS Group assumed coverage on shares of Spyre Therapeutics in a research note on Sunday, October 11th. They set a “buy” rating and a $120.00 price objective for the company. Finally, Robert W. Baird set a $120.00 price objective on Spyre Therapeutics in a report on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $110.53.

Get Our Latest Stock Report on SYRE

Insider Buying and Selling

In related news, insider Heidy King-Jones sold 28,933 shares of the business’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $91.03, for a total transaction of $2,633,770.99. Following the transaction, the insider directly owned 2,845 shares in the company, valued at approximately $258,980.35. The trade was a 91.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Cameron Turtle sold 15,000 shares of the company’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $92.01, for a total transaction of $1,380,150.00. Following the sale, the chief executive officer directly owned 537,540 shares in the company, valued at $49,459,055.40. This trade represents a 2.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 138,064 shares of company stock worth $12,349,518. Insiders own 15.69% of the company’s stock.

About Spyre Therapeutics

(Free Report)

Spyre Therapeutics is a clinical-stage biotechnology company developing antibody-based medicines for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Its research focuses on therapies designed to target immune pathways involved in these conditions. The company’s pipeline includes investigational antibodies targeting TL1A, IL-23 and integrin α4β7, as well as potential combinations of these approaches. Spyre has no approved products, and its candidates remain in development.

Read More

Want to see what other hedge funds are holding SYRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report).

Institutional Ownership by Quarter for Spyre Therapeutics (NASDAQ:SYRE)

Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.